Slides
Page 1
2026 Interim Results 30 September 2026
Page 2
© Novacyt Group of companies Presenters Steve Gibson, Chief Financial Officer • Joined Novacyt in 2017 • Group Finance Director since February 2020, CFO since January 2024 • Over 10 years in financial management at a globally recognised blue-chip, technology company • Broad commercial and international experience, including IPO • CIMA qualified over 15 years Lyn Rees, Chief Executive Officer • CEO of Novacyt Group since 1 May 2024 • 6 years as CEO of Yourgene Health • Drove the acquisition of Elucigene Diagnostics and Coastal Genomics and the fundraising to underpin • Prior to joining Yourgene, was Group CEO at British Biocell International (now BBI Group) for over 9 years • Completed 7 acquisitions during his tenure at BBI Group 2
Page 3
© Novacyt Group of companies Novacyt Group What we do International molecular diagnostics company with a growing portfolio of: • Clinical Assays • Instrumentation • Research Tools With deep focus and expertise across: • Reproductive Health • Precision Medicine • Infectious Disease Clinical IVD assays & DNA size selection qPCR kits for pathogen detection Distributor of life science & diagnostics 3
Page 4
© Novacyt Group of companies Novacyt Group Operational and Post Period Highlights Acquisition of Southern Cross Diagnostics (“SCD”) • Acquired a profitable distributor of diagnostic and life sciences products for an initial cash consideration of AUD$8.5m • Provides direct access to fast-growing Australian diagnostic market • SCD contributed £1.8m of revenue from 2 March to 30 June Launch of Yourgene® Insight DPYD assay • Enables the accurate detection of 19 variants in the DPYD gene, making this the most complete assay on the market • Certification broadens the commercial opportunity for the product across European markets Company restructuring • Workforce reduction largely complete as of September 2026 – c. 60 staff have left • Board were targeting up to £4.0m in cost savings, reducing overall cash burn and strengthening the balance sheet • Majority of savings will be reflected in FY2027 Master Collaboration Agreement with Illumina • Agreement for an initial 5-year period, signalling industry confidence in the Company’s longevity and skill set • Establishes framework for future collaboration in areas of mutual interest • First project agreement signed and work has commenced 4
Page 5
© Novacyt Group of companies 2026 Unaudited Interim Results
Page 6
© Novacyt Group of companies Financial Highlights • Revenue of £11.6m, with Instrumentation up 30% YoY and Clinical up over 20% YoY • Underlying revenue growth of 9%, excluding the impact of revenue generated by Southern Cross Diagnostics (“SCD”) • Gross profit totalled £6.4m, with a margin of 56%, diluted by the impact of SCD sales and acquisition stock uplift adjustment • Opex costs reduced further to £10.3m • EBITDA loss decreased to £3.9m. Adjusted EBITDA loss of £3.6m removing the impact of the SCD stock uplift adjustment • Cash position at 30 June was £8.9m and the Group remains debt free 6
Page 7
© Novacyt Group of companies Revenue by Business Segment £1.8m 16% £.2m 21% £.5m 69% H1 2026 H1 2025 £8.5m 73% £1.3m 11% £0.9m 10% £2.0m 20% £6.9m 70%Clinical Research Use Only Instrumentation Total: £11.6m Total: £9.8m Year-on-Year Growth: ➢ 18% statutory ➢ 9% excluding impact of revenue generated from Southern Cross Diagnostics 7
Page 8
© Novacyt Group of companies Revenue by Geography H1 2026 America £1.5m 13% 11% Europe £5.7m 49% 54% Asia-Pacific £3.8m 33% 29% Middle East & Africa £0.6m 5% 6% H1 2025 Total £11.6m Americas grew more than 30% year-on-year driven primarily by strong instrument demand. Asia-Pacific grew more than 20% year-on-year supported by the continued demand for the Company’s Reproductive Health portfolio 8
Page 9
© Novacyt Group of companies H1 2026 H1 2025 £m £m Revenue 11.6 9.8 Gross profit 6.4 6.5 Gross profit % 56% 66% Operating expenditure (10.3) (10.6) EBITDA (3.9) (4.1) EBITDA % -33% -42% Adjusted EBITDA (3.6) (4.1) Recurring operating loss (5.0) (6.4) Operating loss (5.1) (7.1) Other financial income and expenses (0.7) 0.1 Tax income 0.1 0.3 Loss after tax from continuing operations (5.7) (6.8) Profit / (loss) from discontinued operations (0.1) 0.4 Loss after tax attributable to the owners (5.8) (6.3) Income Statement Gross profit diluted due to the impact of SCD sales being dilutive, the SCD fair value stock uplift adjustment, as part of the PPA process, and reduced Primer Design sales year-on-year (see next slide) 9
Page 10
© Novacyt Group of companies Gross Profit Margin The gross profit margin dropped to 56% in H1 2026 (H1 2025: 66%) impacted by: i) SCD sales being dilutive at a typical distributor margin (circa 40%) ii) Release of the stock uplift adjustment related to the fair value of stock acquired as part of the acquisition of SCD, which will cease once all acquired stock is sold iii) Reduced sales in Primer Design which generates a margin of over 80% 10
Page 11
© Novacyt Group of companies H1 2026 H1 2025 £m £m Revenue 11.6 9.8 Gross profit 6.4 6.5 Gross profit % 56% 66% Operating expenditure (10.3) (10.6) EBITDA (3.9) (4.1) EBITDA % -33% -42% Adjusted EBITDA (3.6) (4.1) Recurring operating loss (5.0) (6.4) Operating loss (5.1) (7.1) Other financial income and expenses (0.7) 0.1 Tax income 0.1 0.3 Loss after tax from continuing operations (5.7) (6.8) Profit / (loss) from discontinued operations (0.1) 0.4 Loss after tax attributable to the owners (5.8) (6.3) Income Statement Includes £0.5m of SCD Opex. Excluding this, underlying Opex reduction of £0.8m as cost savings initiatives have flown through Gross profit diluted due to the impact of SCD sales being dilutive, the SCD fair value stock uplift adjustment, as part of the PPA process, and reduced Primer Design sales year-on-year 11
Page 12
© Novacyt Group of companies Operating Expenditure Closure of IT-IS International Site consolidation programme Investment in R&D Acquisition of SCD Restructuring Post Yourgene acquisition synergies 12
Page 13
© Novacyt Group of companies H1 2026 H1 2025 £m £m Revenue 11.6 9.8 Gross profit 6.4 6.5 Gross profit % 56% 66% Operating expenditure (10.3) (10.6) EBITDA (3.9) (4.1) EBITDA % -33% -42% Adjusted EBITDA (3.6) (4.1) Recurring operating loss (5.0) (6.4) Operating loss (5.1) (7.1) Other financial income and expenses (0.7) 0.1 Tax income 0.1 0.3 Loss after tax from continuing operations (5.7) (6.8) Profit / (loss) from discontinued operations (0.1) 0.4 Loss after tax attributable to the owners (5.8) (6.3) Income Statement Includes £0.5m of SCD Opex. Excluding this, underlying Opex reduction of £0.8m as cost savings initiatives have flown through Gross profit diluted due to the impact of SCD sales being dilutive, the SCD fair value stock uplift adjustment, as part of the PPA process, and reduced Primer Design sales year-on-year £0.2m (6%) improvement in EBITDA year-on-year Net exceptional costs of £0.1m include: 1. £0.2m of restructuring expenses 2. £0.1m other operating income Excluding the SCD stock uplift adjustment, £0.5m (13%) improvement in EBITDA year-on-year 13
Page 14
© Novacyt Group of companies Summary Balance Sheet Increase in non-current assets due to the goodwill and intangible assets associated with the SCD acquisition Increase in current assets and liabilities due to the inclusion of SCD balances Cash absorption includes £5.2m for the acquisition of SCD, net of cash acquired Increase in non-current liabilities due to the following relating to the SCD acquisition: i) contingent consideration ii) deferred tax liability on temporary timing differences relating to assets acquired Strong balance sheet to support achieving profitability H1 2026 FY 2025 £m £m Non-current assets 17.7 12.6 Inventories 4.5 2.5 Trade and other receivables 6.6 6.1 Cash 8.9 19.1 Current liabilities (6.4) (5.8) Net current assets 13.6 21.9 Non-current liabilities (12.6) (11.1) Net assets 18.7 23.4 14
Page 15
© Novacyt Group of companies H1 2026 Cash Flow 15
Page 16
© Novacyt Group of companies Novacyt Group Investment Summary Stable foundations - operationally ready for growth, cost-base and cash burn reduced, with further initiatives implemented1 Revenue growth on upward trajectory - three half-years of consecutive growth from £9.6m in H2 2024 to £11.6m in H1 2026, with solid gross margin performance Opex costs continue to reduce - from a pro-forma 2023 half year cost of £13.8m to £10.3m in H1 2026. The business remains well funded Robust commercialisation strategy - across each product portfolio; clinical, RUO and instrumentation Inorganic M&A opportunities - this will accelerate path to profitability 2 3 7 Established and growing customer base - further strengthened by the immediately earnings and revenue accretive acquisition of SCD 6 Blue-chip customers - MCA signed with Illumina along with new product launches (DPYD)5 4 16
Page 17
investors@novacyt.com Novacyt Group (UK) Skelton House Lloyd Street North Manchester Science Park Manchester M15 6SH, UK